MCID: CYT018
MIFTS: 19

Cytochrome P450 2d6 Variant malady

Categories: Rare diseases

Aliases & Classifications for Cytochrome P450 2d6 Variant

Aliases & Descriptions for Cytochrome P450 2d6 Variant:

Name: Cytochrome P450 2d6 Variant 50
Human Cytochrome P450 2d6 50
Cytochrome P450 50
Cyp2d6 50

Classifications:



Summaries for Cytochrome P450 2d6 Variant

MalaCards based summary : Cytochrome P450 2d6 Variant, also known as human cytochrome p450 2d6, is related to cytochrome p450 oxidoreductase deficiency and disordered steroidogenesis due to cytochrome p450 oxidoreductase. The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include liver.

Wikipedia : 71 Cytochrome P450 2D6 is an enzyme that in humans is encoded by the CYP2D6 gene. CYP2D6 is primarily... more...

Related Diseases for Cytochrome P450 2d6 Variant

Diseases related to Cytochrome P450 2d6 Variant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 93)
id Related Disease Score Top Affiliating Genes
1 cytochrome p450 oxidoreductase deficiency 12.5
2 disordered steroidogenesis due to cytochrome p450 oxidoreductase 12.4
3 schizophrenia 11.3
4 autoimmune hepatitis 11.3
5 neuroleptic malignant syndrome 11.3
6 substance abuse 11.2
7 multiple chemical sensitivity 11.2
8 tardive dyskinesia 11.2
9 serotonin syndrome 11.2
10 obsessive-compulsive disorder 11.2
11 antley-bixler syndrome with genital anomalies and disordered steroidogenesis 11.0
12 anxiety disorder 10.9
13 debrisoquine sensitivity 10.9
14 gastroparesis 10.9
15 codeine toxicity 10.9
16 hepatitis d 10.9
17 drug-induced hepatitis 10.9
18 attention deficit-hyperactivity disorder 10.9
19 dementia, lewy body 10.9
20 pseudobulbar affect 10.8
21 cyp2d6-related altered drug metabolism 10.8
22 autoimmune disease of gastrointestinal tract 10.8
23 central nervous system disease 10.8
24 toxic oil syndrome 10.8
25 kleptomania 10.8
26 resistance to tamoxifene 10.8
27 antidepressant or antipsychotic toxicity or dose selection 10.8
28 female stress incontinence 10.8
29 psychotic disorder 10.8
30 substance dependence 10.8
31 disease of mental health 10.7
32 leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism 10.7
33 mental depression 10.7
34 parkinson disease, late-onset 10.7
35 hypomyelinating leukodystrophy 13 10.7
36 amelogenesis imperfecta, type 1e 10.7
37 amelogenesis imperfecta, type ib 10.7
38 breast cancer 10.4
39 lung cancer 10.2
40 hepatitis 10.1
41 hepatitis c 9.9
42 leukemia 9.8
43 dementia 9.8
44 cervicitis 9.8
45 prostatitis 9.8
46 prostate cancer 9.8
47 inflammatory bowel disease 9.7
48 systemic lupus erythematosus 9.7
49 squamous cell carcinoma 9.7
50 myoclonus 9.7

Graphical network of the top 20 diseases related to Cytochrome P450 2d6 Variant:



Diseases related to Cytochrome P450 2d6 Variant

Symptoms & Phenotypes for Cytochrome P450 2d6 Variant

Drugs & Therapeutics for Cytochrome P450 2d6 Variant

Drugs for Cytochrome P450 2d6 Variant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 199)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Bupropion Approved Phase 4,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
3
Lactulose Approved Phase 4 4618-18-2 11333
4
Citalopram Approved Phase 4 59729-33-8 2771
5
Paroxetine Approved, Investigational Phase 4,Phase 1 61869-08-7 43815
6
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Montelukast Approved Phase 4 158966-92-8 5281040
9
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
10
Methamphetamine Approved, Illicit Phase 4,Phase 2 537-46-2 10836
11 Analgesics Phase 4,Phase 1,Phase 2
12
Serotonin Phase 4,Phase 2,Phase 1 50-67-9 5202
13 Serotonin Agents Phase 4,Phase 2,Phase 1
14 Narcotics Phase 4,Phase 1
15 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
16 Neurotransmitter Agents Phase 4,Phase 2,Phase 1
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 1
18 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Phase 1
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 1,Phase 2
20 Analgesics, Opioid Phase 4,Phase 1
21 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
22 Dopamine Agents Phase 4,Phase 2,Phase 1
23 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 1
24 Antidepressive Agents Phase 4,Phase 2,Phase 1
25 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 1
26 Psychotropic Drugs Phase 4,Phase 2,Phase 1
27 Respiratory System Agents Phase 4,Phase 1
28 Central Nervous System Depressants Phase 4,Phase 1
29 Rosuvastatin Calcium Phase 4 147098-20-2
30 Adrenergic Agents Phase 4,Phase 2
31 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 1,Phase 2
32 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 1,Phase 2
33 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 1,Phase 2
34 Hormone Antagonists Phase 4,Phase 1,Phase 2
35 Hormones Phase 4,Phase 1,Phase 2
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2
37 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
38 Anti-Asthmatic Agents Phase 4
39 Hypolipidemic Agents Phase 4
40 Anti-Infective Agents Phase 4,Phase 1,Phase 2
41 Anticholesteremic Agents Phase 4
42 Antidepressive Agents, Tricyclic Phase 4
43 Leukotriene Antagonists Phase 4
44 Lipid Regulating Agents Phase 4
45 Antimetabolites Phase 4
46 Anti-Retroviral Agents Phase 4
47 Reverse Transcriptase Inhibitors Phase 4
48 Atomoxetine Hydrochloride Phase 4
49 Autonomic Agents Phase 4,Phase 2
50 Antiviral Agents Phase 4

Interventional clinical trials:

(show all 30)
id Name Status NCT ID Phase
1 Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4
2 Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study Unknown status NCT00785603 Phase 4
3 CYP2B6 Genetics and Drug Interactions in Healthy Volunteers Completed NCT02401256 Phase 4
4 Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Completed NCT00380692 Phase 4
5 Fluoxetine in Pediatric Body Dysmorphic Disorder Completed NCT00245635 Phase 4
6 Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants (CYSCE) Recruiting NCT01778907 Phase 4
7 Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns Active, not recruiting NCT02078180 Phase 4
8 The Impact of Genetic Variation in CYP2D6 on the Pharmacokinetics and Pharmacodynamics of Methamphetamine Withdrawn NCT01529892 Phase 4
9 CYP2C9 Activity Evaluated With a Simple Finger Prick Completed NCT01026714 Phase 1, Phase 2
10 Study of Medical Treatment for Methamphetamine Addiction Completed NCT00833443 Phase 2
11 Fluoxetine for Visual Recovery After Ischemic Stroke Recruiting NCT02737930 Phase 2
12 Role of CYP2B6, CYP3A4, and MDR1 in the Metabolic Clearance of Methadone Unknown status NCT00504413 Phase 1
13 Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene Completed NCT01289756 Phase 1
14 CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk Unknown status NCT01050400
15 Use of Pharmacogenetics in the Treatment of Children With Autistic Spectrum Disorders Unknown status NCT00859664
16 Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM Completed NCT02428660
17 YouScript IMPACT Registry Completed NCT02191358
18 Pharmacogenetic Testing Among Home Health Patients Completed NCT02378220
19 A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease Completed NCT01944436
20 Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations Completed NCT02789527
21 Pharmacogenetics of Bupropion Metabolism Completed NCT00791869
22 The MATCH (Medication Aids for Tobacco Cessation and Health) Study Completed NCT02146911
23 Effect of Ethanol and Genetic Polymorphisms on Bupropion Metabolism Completed NCT00330434
24 Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm Completed NCT01632267
25 Predicting Medication Response in Obsessive Compulsive Disorder Completed NCT01404871
26 Precision Medicine Guided Treatment for Cancer Pain Recruiting NCT02664350
27 A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program Recruiting NCT02297126
28 PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions Recruiting NCT03093818
29 Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics Active, not recruiting NCT01118858
30 Development of Cocktail for Measuring the Activity of Important Cytochrome P450 Enzymes Terminated NCT00981929

Search NIH Clinical Center for Cytochrome P450 2d6 Variant

Genetic Tests for Cytochrome P450 2d6 Variant

Anatomical Context for Cytochrome P450 2d6 Variant

MalaCards organs/tissues related to Cytochrome P450 2d6 Variant:

39
Liver

Publications for Cytochrome P450 2d6 Variant

Articles related to Cytochrome P450 2d6 Variant:

id Title Authors Year
1
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. ( 9012401 )
1997

Variations for Cytochrome P450 2d6 Variant

Expression for Cytochrome P450 2d6 Variant

Search GEO for disease gene expression data for Cytochrome P450 2d6 Variant.

Pathways for Cytochrome P450 2d6 Variant

GO Terms for Cytochrome P450 2d6 Variant

Sources for Cytochrome P450 2d6 Variant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....